CommercialCoverageMedium impact
06.02.18m, Pharmacogenetics and Metabolite Monitoring for Using Azathioprine (AZA)/6-Mercaptopurine (6-MP) Therapy (Independence Administrators)
Independence Blue Cross·Gastroenterology, Rheumatology, Oncology +1 more·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross (IBX) has reissued their policy on pharmacogenetics and metabolite monitoring for azathioprine/6-mercaptopurine therapy, effective October 1, 2025. This is a policy reissue rather than a substantive change, but billing teams should review the updated policy document for any modifications to coverage criteria or documentation requirements.
Action Required
By October 1, 2025: Billing team must review the updated IBX policy 06.02.18m for pharmacogenetics and metabolite monitoring related to azathioprine/6-mercaptopurine therapy. Access the full policy document from the source URL to identify any changes to coverage criteria, prior authorization requirements, or documentation standards that may affect claim submission.